Hair loss might be the most commercially aggressive corner of men's health. The moment you search for it, you're in a funnel — supplements, lasers, clinics, subscriptions. Podcasts are one of the few places the topic gets discussed at length without a checkout page attached. Here's what's worth your ears before your wallet.
Why hair loss is suddenly everywhere
The condition didn't change — half of men show significant androgenetic loss by fifty, and it often starts in the twenties — but three things changed around it. Telehealth turned treatment into e-commerce: companies built entire business models on prescribing finasteride and minoxidil through an online questionnaire, then spent heavily on podcast ads and social media to normalize the conversation. The destigmatization worked both ways: men talk about it now, which is good, and are marketed to relentlessly, which is mixed. Second, medical tourism exploded — Istanbul alone performs an enormous share of the world's hair transplants, and before-and-after content became its own social media genre. Third, the science conversation got popular: a few huge podcast episodes moved hair loss from embarrassing secret to optimization topic, sitting naturally next to sleep scores and protein targets. The result: more men treating earlier (genuinely good, since prevention beats regrowth) and more money extracted from anxiety than ever.
Start here: the Huberman episode
Huberman Lab's deep dive — "The Science of Healthy Hair, Hair Loss and How to Regrow It" — is the single most useful mainstream episode on the subject. He walks through the biology of the hair cycle (anagen, catagen, telogen, and why shed hairs aren't the real measure of loss), what dihydrotestosterone actually does to genetically susceptible follicles, and then the evidence hierarchy treatment by treatment: minoxidil topical and low-dose oral, finasteride and dutasteride, microneedling as an evidence-supported adjunct, ketoconazole shampoo's modest contribution, and why most supplements have thin support outside genuine deficiency. The episode's core message is sobering and useful: the earlier you act, the more you keep, because maintaining follicles is far easier than resurrecting them. If you listen to one hour on this topic, it's this one.
The dermatology shows
Dermasphere — a podcast made by academic dermatologists reviewing the literature for other clinicians — covers hair as the research publishes: new androgenetic alopecia data, the JAK-inhibitor revolution in alopecia areata (the autoimmune form), and the quiet shift toward low-dose oral minoxidil, a decades-old blood pressure drug whose off-label revival at tiny doses has genuinely changed clinical practice in recent years. It's technical, but eavesdropping on what dermatologists tell each other is the best filter against marketing you'll find anywhere.
Skincare Anarchy interviews founders and dermatologists across the beauty-science industry, including hair brands and clinic chains — useful for understanding the business machinery, with the standing caveat that founder interviews are friendly territory by design.
The men's health wing
More Plates More Dates is where the finasteride debate actually happens. Derek — who built a large audience on hormone pharmacology and founded a health-optimization company — covers DHT, 5-alpha-reductase inhibitors and their side-effect controversies in more depth than any medical show will: the sexual side-effect data (low single-digit percentages in trials, hotly contested in communities), the post-finasteride syndrome debate, topical finasteride as a compromise, and dutasteride's stronger suppression. The tone is bodybuilding-internet, but the pharmacological literacy is real, and he engages the scary anecdotes rather than dismissing them — which, ironically, makes the drugs less frightening, because you hear the base rates. Attia and Huberman have both also covered 5-AR inhibitors and the hormone side in broader endocrine episodes with urologists like Dr. Kyle Gillett.
The debate worth understanding: finasteride fear
The central tension across all this coverage is a genuinely interesting risk-communication problem. Finasteride has decades of data showing it stops loss for the large majority of men who take it, with side effects affecting a small minority — yet online fear of it is enormous, amplified by worst-case anecdotes. The podcast world handles this split: the medical shows emphasize the trial data and the nocebo effect (side-effect rates rise when men are warned to expect them), while the community shows take reported harms seriously and discuss exit ramps and alternatives. Listening to both sides is the honest preparation for a conversation with a doctor — which, for a drug you may take for decades, is worth having properly rather than via checkout flow.
What the credible coverage agrees on
Across all of it, the same picture. Two treatments have decades of evidence: minoxidil and finasteride, ideally together. Microneedling has decent supporting data as an add-on. Transplants work but are surgery, cost thousands, and only make sense once loss is stabilized with medication — otherwise you're transplanting into a retreating hairline. The supplement aisle is mostly hope in capsule form, with exceptions for documented deficiencies (iron, vitamin D) and modest evidence for a few compounds like saw palmetto, which the shows generally describe as finasteride's much weaker cousin. And telehealth access is genuinely convenient — most treatment now starts with an online visit rather than a urologist's office — with the standing advice to use licensed services prescribing real, regulated medications.
The pattern worth noticing, audible across every credible hour on this subject: the boring generic drugs are the answer, and the advertisements all suggest they aren't. Choose your information sources accordingly — and act early, because every expert agrees on that part.
Episodes referenced come from shows tracked in Reason.fm's Health & Fitness and Medicine charts.